SWGC
FDMT icon

Summit Wealth Group (Colorado)’s 4D Molecular Therapeutics FDMT Stock Holding History

Summit Wealth Group (Colorado)’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,204
Closed -$1.47M – 388
2025
Q3 		$1.47M Buy
+13,204
New +$78.9K 0.16% 115

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Summit Wealth Group (Colorado)'s FDMT Position: Q4 2025 in Review

Summit Wealth Group (Colorado) sold out of 4D Molecular Therapeutics (FDMT) in Q4 2025, closing a stake of 13,204 shares — an estimated $1.47M sold.

Summit Wealth Group (Colorado) first reported a position in FDMT in Q3 2025 and held it in 1 quarter. The position peaked at $1.47M in Q3 2025. 153 funds tracked by Wall St. Rank hold FDMT as of Q4 2025.

  • Summit Wealth Group (Colorado) reported no remaining 4D Molecular Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Summit Wealth Group (Colorado) sold 13,204 4D Molecular Therapeutics shares in Q4 2025, an estimated $1.47M.
  • Summit Wealth Group (Colorado) first reported a position in 4D Molecular Therapeutics in Q3 2025 and held it in 1 quarter.
  • Summit Wealth Group (Colorado)'s 4D Molecular Therapeutics position peaked at $1.47M in Q3 2025.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2025.

Based on Summit Wealth Group (Colorado)'s 13F filing for Q4 2025, filed 4 Feb 2026.